(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adults receiving once-weekly 1.2 mg MET-097 lost 12.5% ...

ATLANTA — The investigational ultra long-acting injectable GLP-1 receptor agonist (RA) MET-097 produced up to 14% weight loss, with the potential for improved tolerability compared with other GLP-1 ...

For some patients, OCT exams may show retinal neurovascular changes associated with early cerebral alterations in Alzheimer disease. Optical coherence tomography (OCT) exams can show retinal ...

US obesity drug developer Metsera (Nasdaq: MTSR) presented detailed results from two Phase IIb trials for its weight-loss drug candidate, MET-097i, at ObesityWeek 2025. The presentation highlighted a ...

The Department of Education (DepEd) remains steadfast in promoting transparency, integrity, and accountability by making basic education data accessible to the public which empowers internal and ...

What is the current share price of Scalare Partners Holdings Limited (SCP)? Scalare Partners Holdings Limited's (SCP) current share price is $0.10. This constitutes a price movement of 8.99% when ...

The functions in the SCP package are all developed around the Seurat object and are compatible with other Seurat functions. Now, you can run PrepareEnv() to create the python environment for SCP. If ...

All the Latest Game Footage and Images from SCP: Classified Site Games metadata is powered by IGDB.com We may earn a commission when you buy through links on our ...

Metsera, Inc. presents four studies on GLP-1 receptor agonist MET-097i at the ADA conference, showcasing clinical and preclinical data. Metsera, Inc., a biopharmaceutical company focused on obesity ...